[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100492877":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":15,"responsibleParty":51,"collaborators":7,"id":53,"slug":7,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":7,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":7,"enrollmentInfo":61,"targetDuration":7,"studyType":64,"phases":7,"briefSummary":65,"conditions":66,"keywords":7,"overallStatus":18,"whyStopped":7,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Intellia Therapeutics","INDUSTRY",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":13,"email":14},"Trial Manager at Intellia","CONTACT","1-857-285-6200","Ext. 6","medicalinformation@intelliatx.com",[16,27,35,43],{"facility":17,"status":18,"city":19,"state":7,"zip":7,"country":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":7},"Clinical Trial Site","RECRUITING","Paris","France",{"type":22,"coordinates":23},"Point",[24,25],2.3488,48.85341,{"lat":25,"lon":24},{"facility":17,"status":18,"city":28,"state":7,"zip":7,"country":29,"cosmosGeoPoint":30,"geoPoint":34,"contacts":7},"Auckland","New Zealand",{"type":22,"coordinates":31},[32,33],174.76349,-36.84853,{"lat":33,"lon":32},{"facility":17,"status":18,"city":36,"state":7,"zip":7,"country":37,"cosmosGeoPoint":38,"geoPoint":42,"contacts":7},"Umeå","Sweden",{"type":22,"coordinates":39},[40,41],20.25972,63.82842,{"lat":41,"lon":40},{"facility":17,"status":18,"city":44,"state":7,"zip":7,"country":45,"cosmosGeoPoint":46,"geoPoint":50,"contacts":7},"London","United Kingdom",{"type":22,"coordinates":47},[48,49],-0.12574,51.50853,{"lat":49,"lon":48},{"type":52,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100492877",false,"NCT05697861","Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001","Long-Term Follow-Up of Subjects Treated With NTLA-2001","Inclusion Criteria:\n\n1. A subject has completed or discontinued from an Intellia-sponsored clinical study in which a complete or partial dose of NTLA-2001 was received.\n2. A subject has provided informed consent for the LTFU study.\n\nExclusion Criteria:\n\nNone","ALL","18 Years",{"count":62,"type":63},72,"ESTIMATED","OBSERVATIONAL","This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.",[67,68,69],"Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy","Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy","Wild-Type Transthyretin Cardiac Amyloidosis","2025-08-20",{"date":72,"type":73},"2025-08-26","ACTUAL",{"date":75,"type":73},"2023-07-10",{"date":77,"type":63},"2038-03",{"name":5,"class":6},4]